Browsing by Author "Arteaga, Antonio"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Association between proinsulin, insulin, proinsulin/insulin ratio, and insulin resistance status with the metabolic syndrome
    (2007) Pivatto, Ivana; Bustos, Patricia; Amigo, Hugo; Acosta, Ana Maria; Arteaga, Antonio
    The Metabolic Syndrome (MS) constitutes an independent risk factor of cardiovascular disease. There is evidence that proinsulin blood levels and the proinsulin/insulin ratio are associated to the MS. The purpose of this study was to compare proinsulin and insulin, insulin resistance index, and the proinsulin/insulin ratio as predictors of MS. This is a cross-sectional study involving 440 men and 556 women with a mean age of 24 years. Diagnosis of MS was made according to the National Cholesterol Education Program Adult Treatment Panel III. Blood levels of insulin and proinsulin were measured, and the insulin resistance status was estimated using the homeostatic model assessment (HOMA-IR). The prevalence of MS was 10.1%. HOMA-IR was the best MS risk factor for both women and men (OR = 2.04; 95% CI: 1.68-2.48 and 1.09; 95% CI: 1.05-1.13, respectively). HOMA-IR presented the best positive predictive value for MS: 22% and 36% for men and women, respectively, and was the best MS indicator. The proinsulin/insulin ratio did not show significant association with MS. HOMA-IR, proinsulin, and insulin presented good negative predictive values for both genders that could be used to identify an at-risk population.
  • Thumbnail Image
    Item
    Molecular diagnosis and combined lipid lowering therapy of heterozygous familial hypercholesterolemia. Report of one case
    (SOC MEDICA SANTIAGO, 2007) Arteaga, Antonio; Cuevas, Ada; Rigotti, Attilio; Gonzalez, Francisco; Castillo, Sergio; Mata, Pedro; Alonso, Rodrigo
    Heterozygous familial hypercholesterolemia affects one every 400 individuals, is caused by mutations in the LDL receptor gene and is associated with premature coronary artery disease. Nowadays, LDL cholesterol can be efficiently reduced with the new therapies to reduce blood lipids. We report a female patient who consulted in 1975, when she was 46 years old, for severe hypercbolesterolemia. In 2003, a sample of leukocyte DNA was obtained and the uncommon 1705 + 1G > A mutation of the LDL receptorgene was detected. No mutations in the apolipoprotein B gene were,found. The patient was treated successfully with simvastatin SO mg/day and ezetimibe 10 mg/day and LDL cholesterol levels were reduced below 200 mg/dl.